Abstract
It is well established that the synthesis of extracellular matrix (ECM) in mesangial cells is a major determinant of diabetic kidney disease (DKD). Elucidating the major players in ECM synthesis may be helpful to provide promising candidates for protecting against DKD progression. tRF3-IleAAT is a tRNA-derived fragment (tRF) produced by nucleases at tRNA-specific sites, which is differentially expressed in the sera of patients with diabetes mellitus and DKD. In this study we investigated the potential roles of tRFs in DKD. Db/db mice at 12 weeks were adapted as a DKD model. The mice displayed marked renal dysfunction accompanied by significantly reduced expression of tRF3-IleAAT and increased ferroptosis and ECM synthesis in the kidney tissues. The reduced expression of tRF3-IleAAT was also observed in high glucose-treated mouse glomerular mesangial cells. We administered ferrostatin-1 (1 mg/kg, once every two days, i.p.) to the mice from the age of 12 weeks for 8 weeks, and found that inhibition of the onset of ferroptosis significantly improved renal function, attenuated renal fibrosis and reduced collagen deposition. Overexpression of tRF3-IleAAT by a single injection of AAV carrying tRF3-IleAAT via caudal vein significantly inhibited ferroptosis and ECM synthesis in DKD model mice. Furthermore, we found that the expression of zinc finger protein 281 (ZNF281), a downstream target gene of tRF3-IleAAT, was significantly elevated in DKD models but negatively regulated by tRF3-IleAAT. In high glucose-treated mesangial cells, knockdown of ZNF281 exerted an inhibitory effect on ferroptosis and ECM synthesis. We demonstrated the targeted binding of tRF3-IleAAT to the 3’UTR of ZNF281. In conclusion, tRF3-IleAAT inhibits ferroptosis by targeting ZNF281, resulting in the mitigation of ECM synthesis in DKD models, suggesting that tRF3-IleAAT may be an attractive therapeutic target for DKD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.
Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52:98–107.
Calle P, Hotter G. Macrophage phenotype and fibrosis in diabetic nephropathy. Int J Mol Sci. 2020;21:2806.
Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80:309–26.
Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28:1023–39.
Zhao JH. Mesangial cells and renal fibrosis. Adv Exp Med Biol. 2019;1165:165–94.
Jiang S, Su H. Cellular crosstalk of mesangial cells and tubular epithelial cells in diabetic kidney disease. Cell Commun Signal. 2023;21:288.
Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. J Biol Eng. 2022;16:19.
Thompson DM, Parker R. Stressing out over tRNA cleavage. Cell. 2009;138:215–9.
Li NS, Shan NY, Lu LG, Wang ZH. tRFtarget: a database for transfer RNA-derived fragment targets. Nucleic Acids Res. 2021;49:D254–D260.
Xie YY, Yao LP, Yu XC, Ruan Y, Li Z, Guo JM. Action mechanisms and research methods of tRNA-derived small RNAs. Signal Transduct Target Ther. 2020;5:109.
Yu XC, Xie YY, Zhang SS, Song XM, Xiao BX, Yan ZL. tRNA-derived fragments: mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections. Theranostics. 2021;11:461–9.
Fagan SG, Helm M, Prehn JHM. tRNA-derived fragments: a new class of non-coding RNA with key roles in nervous system function and dysfunction. Prog Neurobiol. 2021;205:102118.
Zhou JH, Liu SX, Chen Y, Fu Y, Silver AJ, Hill MS, et al. Identification of two novel functional tRNA-derived fragments induced in response to respiratory syncytial virus infection. J Gen Virol. 2017;98:1600–10.
Lu XY, Zhu XY, Yu MY, Na C, Gan WH, Zhang AQ. Profile analysis reveals transfer RNA fragments involved in mesangial cells proliferation. Biochem Biophys Res Commun. 2019;514:1101–7.
Shi HM, Yu MY, Wu Y, Cao YP, Li SW, Qu GT, et al. tRNA-derived fragments (tRFs) contribute to podocyte differentiation. Biochem Biophys Res Commun. 2020;521:1–8.
Huang C, Ding L, Ji JL, Qiao YY, Xia ZH, Shi HM, et al. Expression profiles and potential roles of serum tRNA-derived fragments in diabetic nephropathy. Exp Ther Med. 2023;26:311.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.
Wang LY, Liu YC, Du TT, Yang H, Lei L, Guo MQ, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27:662–75.
Chen X, Li JB, Kang R, Klionsky DJ, Tang DL. Ferroptosis: machinery and regulation. Autophagy. 2021;17:2054–81.
Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco S, Cannata-Ortiz P, Sanchez-Niño MD, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol. 2017;28:218–29.
Li SW, Zheng LS, Zhang J, Liu XJ, Wu ZM. Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy. Free Radic Biol Med. 2021;162:435–49.
Wang JY, Wang YQ, Liu Y, Cai XT, Huang X, Fu WJ, et al. Ferroptosis, a new target for treatment of renal injury and fibrosis in a 5/6 nephrectomy-induced CKD rat model. Cell Death Discov. 2022;8:127.
Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Ren Physiol. 2003;284:F1138–F1144.
Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328.
Liu WJ, Wang XW. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20:18.
Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102:248–60.
Li SW, Liu YW, He XW, Luo XG, Shi HM, Qu GT, et al. tRNA-derived fragments in podocytes with adriamycin-induced injury reveal the potential mechanism of idiopathic nephrotic syndrome. Biomed Res Int. 2020;2020:7826763.
Li D, Zhang H, Wu XQ, Dai Q, Tang SQ, Liu Y, et al. Role of tRNA derived fragments in renal ischemia-reperfusion injury. Ren Fail. 2022;44:815–25.
Ho HJ, Shirakawa H. Oxidative stress and mitochondrial dysfunction in chronic kidney disease. Cells. 2022;12:88.
Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 2016;25:657–84.
Wang JY, Liu Y, Wang YQ, Sun L. The cross-link between ferroptosis and kidney diseases. Oxid Med Cell Longev. 2021;2021:6654887.
Zhang XQ, Li XG. Abnormal iron and lipid metabolism mediated ferroptosis in kidney diseases and its therapeutic potential. Metabolites. 2022;12:58.
Wu Y, Zhao Y, Yang HZ, Wang YJ, Chen Y. HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. Biosci Rep. 2021;41:BSR20202924.
Sheng XH, Shan C, Liu JB, Yang JT, Sun B, Chen DZ. Theoretical insights into the mechanism of ferroptosis suppression via inactivation of a lipid peroxide radical by liproxstatin-1. Phys Chem Chem Phys. 2017;19:13153–9.
Fang XX, Cai ZX, Wang H, Han D, Cheng Q, Zhang P, et al. Loss of cardiac ferritin h facilitates cardiomyopathy via slc7a11-mediated ferroptosis. Circ Res. 2020;127:486–501.
Ding CG, Ding XM, Zheng J, Wang B, Li Y, Xiang HL, et al. miR-182-5p and miR-378a-3p regulate ferroptosis in I/R-induced renal injury. Cell Death Dis. 2020;11:929.
Wang WX, Zhu L, Li HT, Ren WY, Zhuo R, Feng CC, et al. Alveolar macrophage-derived exosomal tRF-22-8BWS7K092 activates Hippo signaling pathway to induce ferroptosis in acute lung injury. Int Immunopharmacol. 2022;107:108690.
Fidalgo M, Shekar PC, Ang YS, Fujiwara Y, Orkin SH, Wang J. Zfp281 functions as a transcriptional repressor for pluripotency of mouse embryonic stem cells. Stem Cells. 2011;29:1705–16.
Deng YR, Peng DZ, Xiao J, Zhao YH, Ding WH, Yuan ST, et al. Inhibition of the transcription factor ZNF281 by SUFU to suppress tumor cell migration. Cell Death Differ. 2023;30:702–15.
Hahn S, Hermeking H. ZNF281/ZBP-99: a new player in epithelial-mesenchymal transition, stemness, and cancer. J Mol Med. 2014;92:571–81.
Qin CJ, Bu PL, Zhang Q, Chen JT, Li QY, Liu JT, et al. ZNF281 regulates cell proliferation, migration and invasion in colorectal cancer through wnt/β-catenin signaling. Cell Physiol Biochem. 2019;52:1503–16.
Laudadio I, Bastianelli A, Fulci V, Carissimi C, Colantoni E, Palone F, et al. ZNF281 promotes colon fibroblast activation in TGFβ1-induced gut fibrosis. Int J Mol Sci. 2022;23:10261.
Pierdomenico M, Palone F, Cesi V, Vitali R, Mancuso AB, Cucchiara S, et al. Transcription factor ZNF281: a novel player in intestinal inflammation and fibrosis. Front Immunol. 2018;9:2907.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (No. 81970664), the Natural Science Foundation of Jiangsu Province (Nos. BK20211385 and BK20191082), the Dedicated Fund for Pediatric Medical Research of Jiangsu Province Medical Association (Nos. SYH-32034-0073 and SYH-32034-0085), and the 789 Outstanding Talent Program of SAHNMU (No. 789ZYRC202090251). We are grateful to the experimental center of the Second Affiliated Hospital of Nanjing Medical University for providing the platform.
Author information
Authors and Affiliations
Contributions
AQZ and HMS conceived and designed the experiments. YYQ, JLJ and WLH performed the experiments and analysed the data. YYQ wrote the manuscript. JLJ helped edit the manuscript, and WLH drew graphic materials. AQZ and HMS revised the manuscript and confirmed the authenticity of all the raw data. GTQ, SWL, XYL, RJ and YFL contributed to the data analysis and graphical abstract. All authors have read and endorsed the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Qiao, Yy., Ji, Jl., Hou, Wl. et al. tRF3-IleAAT reduced extracellular matrix synthesis in diabetic kidney disease mice by targeting ZNF281 and inhibiting ferroptosis. Acta Pharmacol Sin 45, 1032–1043 (2024). https://doi.org/10.1038/s41401-024-01228-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-024-01228-5